PACIFIC Trial Treatment Arms
I cannot provide the treatment arms of the PACIFIC 8 trial because none of the evidence provided contains information about a trial called "PACIFIC 8."
What the Evidence Shows
The evidence contains extensive information about the PACIFIC trial (not PACIFIC 8), which was a phase III randomized trial in stage III non-small-cell lung cancer. 1, 2
PACIFIC Trial Design (Not PACIFIC 8)
The PACIFIC trial had two treatment arms 1:
Durvalumab arm: Patients received durvalumab 10 mg/kg intravenously every 2 weeks for up to 12 months after completing definitive platinum-based concurrent chemoradiotherapy 1, 3
Placebo arm: Patients received matching placebo on the same schedule 1, 4
Randomization was 2:1 (durvalumab:placebo), with 476 patients assigned to durvalumab and 237 to placebo 4, 2
Eligibility criteria included patients with unresectable stage III NSCLC who had stable or responding disease following concurrent platinum-based chemoradiotherapy, with randomization occurring 1-42 days after completing thoracic radiation 1, 3
Important Clarification
If you are asking about a different trial with "PACIFIC 8" in its name, or a substudy/extension of the PACIFIC trial, this information is not available in the provided evidence. The evidence only references the main PACIFIC trial and its follow-up analyses. 1, 3, 4, 2